Cardinal Health ( (CAH) ) has released its Q1 earnings. Here is a breakdown of the information Cardinal Health presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cardinal Health is a global healthcare services and products company that specializes in pharmaceutical and medical products distribution, manufacturing, and data solutions, serving a diverse range of healthcare providers.
Cardinal Health recently announced its first quarter fiscal year 2025 results, showcasing a 4% decline in revenue to $52.3 billion, primarily due to the expiration of a significant customer contract. However, excluding the impact of this contract expiration, the company experienced a 15% revenue growth. The company also reported a 12% increase in non-GAAP operating earnings, driven by strong performance in its Pharmaceutical and Specialty Solutions segment.
Key financial highlights include a rise in GAAP operating earnings to $568 million and a 9% increase in non-GAAP diluted EPS to $1.88. The Pharmaceutical and Specialty Solutions segment profit grew by 16% due to increased brand and specialty pharmaceutical sales and improved generics program performance. Meanwhile, the Global Medical Products and Distribution segment saw a modest 3% revenue increase but faced a decline in segment profit due to higher costs.
Looking ahead, Cardinal Health has raised its fiscal 2025 non-GAAP EPS guidance to a range of $7.75 to $7.90, reflecting confidence in its growth strategy and operational performance. The company remains committed to serving its customers and creating value for shareholders, as highlighted by its recent acquisition and ongoing expansion plans.
